Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Several risk factors including high cholesterol contribute to heart disease. We know that
lowering triglycerides and raising HDL (protective cholesterol) in men reduces the risk for
heart disease. We expect that women will share this same benefit because the combination of
high triglycerides and low HDL appears to be a more important risk for heart disease in
women. Niacin reduces triglycerides and raises HDL. We also expect to see improvement in
markers of inflammation and clot formation and blood vessel health, which we hypothesize
should all confer a reduced risk of heart disease in women.
Women already taking lipid lowering statin will receive niacin therapy. We will measure blood
lipid levels, markers of inflammation and clotting as well as a non-invasive measure of blood
vessel reactivity. After 3 months of therapy we will repeat these measures.
Phase:
Phase 4
Details
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborators:
General Clinical Research Center (GCRC) Kos Pharmaceuticals